Alpha Thalassemia Market Size, Share, Growth, Trends, and Global Industry Analysis: By Type of Disease (Hb Bart Syndrome, HbH Disease, Silent Carrier State-Trait), By Treatment (Blood Transfusions, Iron Chelation, Bone Marrow, Stem Cell Transplant, Gene Therapy), By Product (Tablet, Capsules, Injectables), By Distributional Channel (Online Distribution, Offline Distribution), By Route of Administration (Oral, Parenteral, Others), By End-user (Hospitals, Specialty Clinics, Others) and Region

Alpha Thalassemia Market size was valued at US$ 3,138.7 million in 2023 and is anticipated to grow at a CAGR of 4.9% from 2024-2030. Market refers to the pharmaceutical or healthcare market related to the condition known as alpha thalassemia. Alpha thalassemia is an inherited blood disorder that affects the production of hemoglobin, the protein responsible for carrying oxygen in red blood cells. This disorder results from gene mutations that lead to reduced or absent production of alpha-globin chains, a component of hemoglobin. The market for alpha thalassemia primarily involves the development, production, and distribution of therapies and treatments aimed at managing the symptoms and complications associated with the condition.

Some of these treatments may include blood transfusions, iron chelation therapy to manage iron overload, and bone marrow transplantation in severe cases. The prevalence of alpha thalassemia carriers (individuals with one abnormal gene) can vary significantly in different populations within these regions. For instance, according to National Organization for Rare Disorders, as much as 5% of the world's population carries an alpha-thalassemia variant. Moreover, the introduction of newer drug products by many market players may aim to influence significant research and development in the market. For instance, Novartis launched Adakveo (Crizanlizumab) for the treatment of sickle cell disease. Adakveo is supplied as a solution for intravenous infusion.

Key Developments

• In November 2019, Bristol Myers Squibb in global collaboration with Acceleron received FDA approval for its Reblozyl (luspatercept-aamt) for the treatment of severe hemolytic anemia in adult patients, which is approved to be used as adjuvant therapy in treating thalassemia.
• In June 2021, Protagonist Therapeutics drug Rusfertide (PTG-300) was given the breakthrough therapy designation by the Food and Drug Administration (FDA) as a potential therapeutic option for polycythemia vera patients to decrease erythrocytosis in individuals who do not need additional treatment for thrombocytosis and/or leucocytosis.